An open-label pharmacokinetic study of TS-172 in patients on hemodialysis
- Conditions
- Hyperphosphatemia
- Registration Number
- jRCT2031240681
- Lead Sponsor
- Taisho Pharmaceutical Co., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- Male
- Target Recruitment
- 6
(1) Japanese male patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to the screening test (2) Patients aged >= 18 and < 75 years at the time of obtaining informed consent
(1) Patients with gastric or intestinal ulceration or a history of them within the past year prior to the date of initiation of treatment, or patients with inflammatory bowel disease or irritable bowel syndrome, or a history of these within the past 5 years prior to the date of initiation of treatment (2) Patients scheduled for renal transplantation, home hemodialysis or change of dialysis facility (transfer or temporary dialysis at other hospital) during the study period (3) Patients who frequently experience diarrhea (defined as Bristol Stool Scale score of 6 or higher)
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method